Vimian Group AB (VIMIAN) - Net Assets
Based on the latest financial reports, Vimian Group AB (VIMIAN) has net assets worth Skr708.80 Million SEK (≈ $76.28 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.11 Billion ≈ $119.43 Million USD) and total liabilities (Skr401.00 Million ≈ $43.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read VIMIAN total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr708.80 Million |
| % of Total Assets | 63.87% |
| Annual Growth Rate | 340.5% |
| 5-Year Change | 97.64% |
| 10-Year Change | N/A |
| Growth Volatility | 129502.9 |
Vimian Group AB - Net Assets Trend (2017–2025)
This chart illustrates how Vimian Group AB's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Vimian Group AB for the complete picture of this company's asset base.
Annual Net Assets for Vimian Group AB (2017–2025)
The table below shows the annual net assets of Vimian Group AB from 2017 to 2025. For live valuation and market cap data, see market value of Vimian Group AB.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr708.80 Million ≈ $76.28 Million |
+0.33% |
| 2024-12-31 | Skr706.50 Million ≈ $76.03 Million |
+34.13% |
| 2023-12-31 | Skr526.71 Million ≈ $56.68 Million |
+9.39% |
| 2022-12-31 | Skr481.50 Million ≈ $51.82 Million |
+34.26% |
| 2021-12-31 | Skr358.64 Million ≈ $38.60 Million |
+30.77% |
| 2020-12-31 | Skr274.25 Million ≈ $29.51 Million |
+427.17% |
| 2019-12-31 | Skr52.02 Million ≈ $5.60 Million |
+165.57% |
| 2018-12-31 | Skr19.59 Million ≈ $2.11 Million |
+391680.00% |
| 2017-12-31 | Skr5.00K ≈ $538.08 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vimian Group AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10900000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr109.00 Million | 15.60% |
| Common Stock | Skr100.00K | 0.01% |
| Other Comprehensive Income | Skr-36.37 Million | -5.20% |
| Other Components | Skr626.17 Million | 89.59% |
| Total Equity | Skr698.90 Million | 100.00% |
Vimian Group AB Competitors by Market Cap
The table below lists competitors of Vimian Group AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SEPLAT ENERGY (DI) NA-50
F:134
|
$1.70 Billion |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
$1.70 Billion |
|
BASF India Limited
NSE:BASF
|
$1.70 Billion |
|
Magnite Inc
NASDAQ:MGNI
|
$1.71 Billion |
|
F&F Co Ltd
KO:383220
|
$1.70 Billion |
|
CITIC Guoan Information Industry Co Ltd
SHE:000839
|
$1.70 Billion |
|
Monarch Casino & Resort Inc
NASDAQ:MCRI
|
$1.70 Billion |
|
Chongqing Iron & Steel Co Ltd Class A
SHG:601005
|
$1.70 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vimian Group AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 699,900,000 to 698,900,000, a change of -1,000,000 (-0.1%).
- Net income of 31,300,000 contributed positively to equity growth.
- New share issuances of 10,500,000 increased equity.
- Other comprehensive income decreased equity by 39,872,939.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr31.30 Million | +4.48% |
| Share Issuances | Skr10.50 Million | +1.5% |
| Other Comprehensive Income | Skr-39.87 Million | -5.71% |
| Other Changes | Skr-2.93 Million | -0.42% |
| Total Change | Skr- | -0.14% |
Book Value vs Market Value Analysis
This analysis compares Vimian Group AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 22.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 149419.60x to 22.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr0.00 | Skr30.10 | x |
| 2018-12-31 | Skr0.05 | Skr30.10 | x |
| 2019-12-31 | Skr0.11 | Skr30.10 | x |
| 2020-12-31 | Skr0.59 | Skr30.10 | x |
| 2021-12-31 | Skr1.02 | Skr30.10 | x |
| 2022-12-31 | Skr1.20 | Skr30.10 | x |
| 2023-12-31 | Skr1.16 | Skr30.10 | x |
| 2024-12-31 | Skr1.39 | Skr30.10 | x |
| 2025-12-31 | Skr1.33 | Skr30.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vimian Group AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.36%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.59x
- Recent ROE (4.48%) is above the historical average (3.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -4.12% | -9.75% | 0.24x | 1.73x | Skr-2.71 Million |
| 2019 | -3.00% | -5.00% | 0.25x | 2.42x | Skr-5.32 Million |
| 2020 | 23.57% | 38.33% | 0.30x | 2.04x | Skr30.39 Million |
| 2021 | 1.84% | 3.80% | 0.27x | 1.79x | Skr-29.16 Million |
| 2022 | -1.49% | -2.56% | 0.30x | 1.92x | Skr-55.38 Million |
| 2023 | 1.87% | 2.97% | 0.34x | 1.85x | Skr-42.80 Million |
| 2024 | 2.64% | 4.94% | 0.34x | 1.59x | Skr-51.49 Million |
| 2025 | 4.48% | 7.36% | 0.38x | 1.59x | Skr-38.59 Million |
Industry Comparison
This section compares Vimian Group AB's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $179,870,049
- Average return on equity (ROE) among peers: -31.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vimian Group AB (VIMIAN) | Skr708.80 Million | -4.12% | 0.57x | $1.70 Billion |
| AroCell AB (AROC) | $80.41 Million | -20.15% | 0.14x | $13.39 Million |
| Devyser Diagnostics AB (DVYSR) | $431.44 Million | -10.65% | 0.16x | $168.47 Million |
| Immunovia publ AB (IMMNOV) | $243.80 Million | -59.49% | 0.23x | $14.70 Million |
| Prostatype Genomics AB (PROGEN) | $35.91 Million | -43.53% | 0.12x | $4.83 Million |
| SenzaGen AB (SENZA) | $107.79 Million | -25.34% | 0.03x | $17.21 Million |
About Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic… Read more